ProQR Therapeutics NV (MEX:PRQRN) Interest Expense: MXN0.0 Mil (TTM As of Mar. 2026)


MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
44 GF Score
Price MXN36.00
GF Value MXN46.47
! 4 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Interest Expense?

ProQR Therapeutics NV MEX:PRQRN 44 Interest Expense is MXN0.0 Mil as of Mar. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 44/100 and a GF Value™ of MXN46.47. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ProQR Therapeutics NV's interest expense for the three months ended in Mar. 2026 was MXN 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ProQR Therapeutics NV's Operating Income for the three months ended in Mar. 2026 was MXN -284.5 Mil. ProQR Therapeutics NV's Interest Expense for the three months ended in Mar. 2026 was MXN 0.0 Mil. GuruFocus does not calculate ProQR Therapeutics NV's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ProQR Therapeutics NV  (MEX:PRQRN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ProQR Therapeutics NV's Interest Expense for the three months ended in Mar. 2026 was MXN0.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was MXN-284.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was MXN189.1 Mil.

ProQR Therapeutics NV's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate ProQR Therapeutics NV's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. ProQR Therapeutics NV has enough cash to cover all of its debt. Its financial situation is stable.

ProQR Therapeutics NV Interest Expense Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Interest Expense Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.93 -105.89 -22.27 -23.52 -19.59

ProQR Therapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:PRQRN
44GF Score
ProQR Therapeutics NV MEX:PRQRN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of MXN0.0 Mil mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Interest Expense of MXN0.0 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Interest Expense too high?
ProQR Therapeutics NV's current Interest Expense is MXN0.0 Mil. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Interest Expense compare to GALT and HRTX?
ProQR Therapeutics NV's Interest Expense of MXN0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Interest Expense is MXN0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Interest Expense of MXN0.0 Mil. The stock's GF Value™ is MXN46.47, compared to a current price of MXN36.00 — trading 22.5% below its estimated fair value. The current Interest Expense is MXN0.0 Mil. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Interest Expense is MXN0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 22.5% below its estimated GF Value™ of MXN46.47.

Key valuation signals for MEX:PRQRN:

  • Interest Expense: MXN0.0 Mil
  • GF Value™: MXN46.47 vs. price of MXN36.00 (22.5% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
44GF Score

Get the complete analysis for MEX:PRQRN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN46.47
GF Value